What is Ticagrelor used for?

1 INDICATIONS AND USAGE Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a

How does Ticagrelor work?

11 DESCRIPTION Ticagrelor tablets contains ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y 12 ADP-receptor.

What pharmaceutical form is Ticagrelor available in?

Ticagrelor: Tabletki ulegające rozpadowi w jamie ustnej 90 mg

What are the side effects of Ticagrelor?

6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere in the labeling: •Bleeding [see Warnings and Precautions ( 5.1 )] •Dyspnea [see Warnings and Precautions ( 5.3 )] Most common adverse reactions (>5%) are bleeding and dyspnea. ( 5.1 , 5.3 , 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc., at 1-888-375-3784 or FDA at 1-800-FDA-1088or www .fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are

Who should NOT take Ticagrelor?

4 CONTRAINDICATIONS • History of intracranial hemorrhage. ( 4.1 ) • Active pathological bleeding. ( 4.2 ) • Hypersensitivity to ticagrelor or any component of the product. ( 4.3 ) 4.1 History of Intracranial Hemorrhage Ticagrelor tablets are contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies ( 14.1 ) ,( 14.2 )]. 4.2 Active Bleeding Ticagrelor tablets are contraindicated in

Does Ticagrelor interact with other medications?

7 DRUG INTERACTIONS • Avoid use with strong CYP3A inhibitors or CYP3A inducers. ( 7.1 , 7.2 ) • Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent. ( 7.3) • Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. ( 7.4 ) • Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects. ( 7.4 ) • Monitor digoxin levels with initiation of

Can Ticagrelor be used during pregnancy?

8 USE IN SPECIFIC POPULATIONS • Lactation: Breastfeeding not recommended ( 8.2 ) 8.1 Pregnancy Risk Summary Available data from case reports with ticagrelor use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Ticagrelor given to pregnant rats and pregnant rabbits during organogenesis caused structural abnormalities in the offspring at maternal doses about 5 to 7 times the maximum recommende

What precautions should be taken with Ticagrelor?

• Caution should be exercised in patients with history of lung, liver or kidney disease, stomach or bowel bleeding, recent injury, irregular heartbeat, stroke, gout, who are taking other medications, any allergy, elderly, children, during pregnancy and breastfeeding. • It may cause dizziness, do not drive a car or operate machinery while taking this medication. • It may reduce platelet counts; avoid injury or bruising.

What ATC class does Ticagrelor belong to?

Ticagrelor: ATC B01AC24. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OTC

Ticagrelor

90 mg, Tabletki ulegające rozpadowi w jamie ustnej

INN: Ticagrelorum

Data updated: 2026-04-11

Available in:

🇨🇿🇩🇪🇬🇧🇪🇸🇵🇱🇵🇹🇸🇰

Form

Tabletki ulegające rozpadowi w jamie ustnej

Dosage

90 mg

Route

—

Storage

—

About This Product

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.